Therapeutic product candidates


Uveitis is a heterogeneous group of diseases characterized by dangerous inflammation of the uvea. It is responsible for 10-15% of blindness in the US.19 Current treatments include steroids and have serious side effects, limiting their utility. There is an unmet medical need in intermediate, posterior and panuveitis, which present the highest risk for vision loss.

Apitope is developing ATX-UV1 and ATX-UV3 for the treatment of uveitis. ATX-UV1 is currently in the discovery stage targeting Birdshot uveitis, a form of posterior uveitis. The product candidate for clinical development will be nominated in the second half of 2019.

ATX-UV3 is a clinic ready potential product candidate for intermediate uveitis.

19 de Boer J., Wulffraat N. & Rothova A. (2003) Visual loss in uveitis in childhood. Br J Ophthalmol.vol 87(7): 879–884..